Drug Trial Radar · NCT01106677
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,284
Actual
Start
May 2010
Primary completion
Oct 2011
Study completion May 2012
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control.
Conditions
- Diabetes Mellitus, Type 2
Interventions
PlaceboDrug
One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
CanagliflozinDrug
One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
SitagliptinDrug
One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
Metformin immediate releaseDrug
The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 26Time frame: Day 1 (Baseline) and Week 26
Locations
125 sites in 22 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Fountain Valley, California
Site not named
National City, California
Site not named
Northridge, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Bradenton, Florida
Site not named
Brooksville, Florida
Site not named
DeFuniak Springs, Florida
Site not named
Hialeah, Florida
Site not named
Niceville, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Savannah, Georgia
Site not named
Champaign, Illinois
Site not named
Avon, Indiana
Site not named
Fishers, Indiana
Site not named
Franklin, Indiana
Site not named
West Des Moines, Iowa
Site not named
Wichita, Kansas
Site not named
Munfordville, Kentucky
Site not named
Portland, Maine
Site not named
Benzonia, Michigan
Site not named
Interlochen, Michigan
Site not named
Troy, Michigan
Site not named
Picayune, Mississippi
Site not named
Florissant, Missouri
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Mansfield, New Jersey
Site not named
New Hyde Park, New York
Site not named
Asheboro, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Kettering, Ohio
Site not named
Oregon City, Oregon
Site not named
Altoona, Pennsylvania
Site not named
Tipton, Pennsylvania
Site not named
East Providence, Rhode Island
Site not named
Greer, South Carolina
Site not named
Mt. Pleasant, South Carolina
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.